Double Click 728 x 90
Double Click 900 x 250

Novartis, U.S. regulators agree to malaria drug trial against COVID-19


Arhama AltafWeb Editor

20th Apr, 2020. 10:58 am
Double Click 160 x 600
Novartis

REUTERS: Novartis has reached an agreement with U.S. regulators to hold a randomized trial of generic malaria drug hydroxychloroquine against COVID-19 disease in 440 hospitalized patients, the Swiss drug-maker said on Monday.

The decades-old medicine has received U.S. Food and Drug Administration (FDA) emergency use authorization for Coronavirus disease, but so far there is no scientific proof it helps those afflicted.

“We recognize the importance of answering the scientific question of whether hydroxychloroquine will be beneficial for patients with COVID-19 disease,” said John Tsai, Novartis’s top drug developer.

The drug, also used to treat lupus and rheumatoid arthritis, has been promoted by President Donald Trump, with some worried the administration’s advocacy for an unproven medicine for COVID-19 has short-circuited the oversight process.

Double Click 300 x 250

Download BOL News App for latest news